A biopharmaceutical company developing treatments for eye diseases, best known for EYSUVIS, an eye drop approved to treat inflammation and pain after eye surgery. The company, founded in 2009 as Kala Pharmaceuticals and renamed Kala Bio, also developed Inveltys for ocular inflammation. Its name was inspired by the medical journal of the American Academy of Ophthalmology, which in early years was called "Kala" — a nod to the field it serves.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -846.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.